EAACI Congress 2023
BackTezepelumab efficacy in dupilumab-eligible patients: a pooled analysis from the PATHWAY and NAVIGATOR studies
Friday 09 Jun, 13:27 PM -
13:39 PM CEST
Hall Y 03+04
ORAL Session